| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1815-12-10 |
| Identifiers | MRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729 |
| Document date | 1851-09-08 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Fourteen-week review after four cycles: restaging CT, blood counts, iron and thyroid, pain, and goals of care. [S]
Mrs. Lovelace returns a week after her fourth cycle. The restaging CT a week ago shows a partial response. She has had no bleeding. Her average pain is 3 of 10 on long-acting morphine 15 mg twice a day, now with a breakthrough dose only once or twice a week. She has mild tingling in her toes that does not affect walking or buttons. She tires for three or four days after each cycle. Her bowels are regular on the laxatives. She has no rash, diarrhea, cough, or cold intolerance. She is working most mornings. She has stopped betting and is meeting the social worker about her debts. The thyroid test due six weeks into treatment and the ferritin due after the iron infusions were not drawn; both were drawn today. [S]
| Element | Detail |
|---|---|
| Response | Partial response on CT after four cycles |
| Pain | Average 3 of 10; breakthrough dose once or twice a week |
| Neuropathy | Mild tingling in the toes, no loss of function |
| Work | Mathematics most mornings |
| Missed tests | Six-week thyroid test and ferritin drawn today instead |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a few days after each cycle |
| Neurological | Positive | Mild tingling in the toes |
| Endocrine | Negative | No cold intolerance or weight gain |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood better; counseling helps |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 1849-06-03 to 1851-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 1851-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 1851-06-16 to 1851-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 1851-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 1851-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 1851-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 1851-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 1851-06-02 to 1851-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 1851-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 1851-06-30 to 1851-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 1851-06-30 to 1851-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 1851-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1851-09-08 | Body height | 165 | cm | S |
| 1851-09-08 | Body weight | 54 | kg | S |
| 1851-09-08 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 1851-09-08 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1851-09-08 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1851-09-08 | Heart rate | 80 | /min | S |
| 1851-09-08 | Respiratory rate | 16 | /min | S |
| 1851-09-08 | Body temperature | 36.7 | Cel | S |
| 1851-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1851-09-08 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1851-09-08 | Leukocytes [#/volume] in Blood by Automated count | 3.8 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1851-09-08 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 1851-09-08 | Platelets [#/volume] in Blood by Automated count | 172 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1851-09-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1851-09-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 1851-09-08 | Thyrotropin [Units/volume] in Serum or Plasma | 3.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1851-09-08 | Ferritin [Mass/volume] in Serum or Plasma | 210 | ng/mL | 15-150 ng/mL | High | S |
| 1851-09-08 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M | 112 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 1851-09-08 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S | ||
| 1851-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |
Vital signs recorded on 1851-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, not sedated; blood pressure 112/70, pulse 80, weight 54.0 kg |
| Neck | No thyroid enlargement |
| Respiratory | Clear |
| Neurological | Light touch slightly reduced at the toes; vibration and strength normal; grade 1 neuropathy |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.6 g/dL, white cells 3.8, neutrophils 1.9, platelets 172 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.72 mg/dL, eGFR 112, ALT 26 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | TSH 3.4 mIU/L. Protocol deviation: the TSH and free T4 due six weeks after baseline were not drawn, because they were left to be added to the cycle 3 blood tests and were not ordered; drawn today, twelve weeks after baseline. No harm resulted: TSH is normal and she has no thyroid symptoms. Corrective action: a standing order for TSH and free T4 every six weeks while she takes pembrolizumab |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Completed today | Ferritin 210 ng/mL. Protocol deviation: the ferritin due 6 to 8 weeks after the second infusion was not drawn at the preventive visit, which fell in that window; drawn today, twelve weeks after. No harm resulted: stores are replete and hemoglobin is rising. Corrective action: list post-infusion tests on the problem list with their due dates |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | None |
| Examination | Peripheral neuropathy on paclitaxel | Before each paclitaxel cycle | Completed today | Grade 1 sensory neuropathy of the toes |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Completed today | CT a week ago: partial response |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 3 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Regular |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change, and every 3 months | Completed today | Naloxone in date; locked storage; monitoring check clear |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | Periodically | Completed today | PHQ-9 7 |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Completed today | Palliative care physician joined today's conversation |
| Self-management | Goals-of-care conversation | At diagnosis, at each restaging, and with any change | Completed today | Recorded; resuscitation not to be attempted; all other treatment continues |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)
Follow-up: Cycles 5 and 6 every three weeks. Review a week after the last cycle. Next scheduled visit 1851-10-20: twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. [S]